Galectin-3 in patients undergoing ablation of atrial fibrillation

IJC Metabolic and Endocrine

Volumn 5, Issue , 2014, Pages 56-60

  Clementy, Nicolas ^a   Piver, Eric ^a   Benhenda, Nazih ^a   Bernard, Anne ^a   Pierre, Bertrand ^a   Siméon, Edouard ^a   Fauchier, Laurent ^a   Pagès, Jean Christophe ^a   Babuty, Dominique ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Atrial fibrillation; Fibrosis; Galectin 3; Paroxysmal; Persistent

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CHA2DS2 VASC SCORE; CHADS2 SCORE; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PAROXYSMAL HEART ATRIUM FIBRILLATION; QRS COMPLEX; TRANSIENT ISCHEMIC ATTACK;

EID: 84919492907     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2014.10.003     Document Type: Article

References (25)

1. Melgaard L., Rasmussen L.H., Skjøth F., Lip G.Y., Larsen T.B. Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation: A Nationwide Study. Stroke 2014, 45:1331-1337.
2. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57:e101-e198.
3. Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol 2014, 29:20-27.
4. Nattel S., Harada M. Atrial Remodeling and Atrial Fibrillation: Recent Advances and Translational Perspectives. J Am Coll Cardiol 2014, 63:2335-2345.
5. Nattel S., Guasch E., Savelieva I., Cosio F.G., Valverde I., Halperin J.L., et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014, 35:1448-1456.
6. Murakawa Y., Nogami A., Shoda M., Inoue K., Naito S., Kumagai K., et al. The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). Circ J 2014, 78:1091-1096.
7. Milliez P., Deangelis N., Rucker-Martin C., Leenhardt A., Vicaut E., Robidel E., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005, 26:2193-2199.
8. Zou C., Zhang Z., Zhao W., Li G., Ma G., Yang X., et al. Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation. J Transl Med 2013, 11:7.
9. Akoum N., Daccarett M., McGann C., Segerson N., Vergara G., Kuppahally S., et al. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J Cardiovasc Electrophysiol 2011, 22:16-22.
10. Mackinnon A.C., Gibbons M.A., Farnworth S.L., Leffler H., Nilsson U.J., Delaine T., et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012, 185:537-546.
11. Calvier L., Miana M., Reboul P., Cachofeiro V., Martinez-Martinez E., de Boer R.A., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013, 33:67-75.
12. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
13. Yu L., Ruifrok W.P., Meissner M., Bos E.M., van Goor H., Sanjabi B., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
14. de Boer R.A., van Veldhuisen D.J., Gansevoort R.T., Muller Kobold A.C., van Gilst W.H., Hillege H.L., et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012, 272:55-64.
15. de Couto G., Ouzounian M., Liu P.P. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol 2010, 7:334-344.
16. Sánchez-Quintana D., López-Mínguez J.R., Pizarro G., Murillo M., Cabrera J.A. Triggers and anatomical substrates in the genesis and perpetuation of atrial fibrillation. Curr Cardiol Rev 2012, 8:310-326.
17. Stiles M.K., John B., Wong C.X., Kuklik P., Brooks A.G., Lau D.H., et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor". J Am Coll Cardiol 2009, 53:1182-1191.
18. Teh A.W., Kistler P.M., Lee G., Medi C., Heck P.M., Spence S.J., et al. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. J Cardiovasc Electrophysiol 2012, 23:232-238.
19. Xu J., Cui G., Esmailian F., Plunkett M., Marelli D., Ardehali A., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004, 109:363-368.
20. Mahnkopf C., Badger T.J., Burgon N.S., Daccarett M., Haslam T.S., Badger C.T., et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm 2010, 7:1475-1481.
21. Marrouche N.F., Wilber D., Hindricks G., Jais P., Akoum N., Marchlinski F., et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 2014, 311:498-506.
22. Ho J.E., Yin X., Levy D., Vasan R.S., Magnani J.W., Ellinor P.T., et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014, 167:729-734. [e1].
23. Szadkowska I., Wlazeł R.N., Migała M., Szadkowski K., Zielińska M., Paradowski M., et al. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J 2013, 20:577-582.
24. Verma A., Mantovan R., Macle L., De Martino G., Chen J., Morillo C.A., et al. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. Eur Heart J 2010, 31:1344-1356.
25. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam B., Dahlöf B., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712-719.